Compare · LIVN vs NUWE
LIVN vs NUWE
Side-by-side comparison of LivaNova PLC (LIVN) and Nuwellis Inc. (NUWE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and NUWE operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.24B, about 11077.0x NUWE ($382,706).
- Over the past year, LIVN is up 62.1% and NUWE is down 98.5% - LIVN leads by 160.7 points.
- NUWE has been more active in the news (10 items in the past 4 weeks vs 5 for LIVN).
- LIVN has more recent analyst coverage (20 ratings vs 1 for NUWE).
- Company
- LivaNova PLC
- Nuwellis Inc.
- Price
- $77.19+3.15%
- $0.14-1.23%
- Market cap
- $4.24B
- $382,706
- 1M return
- +7.39%
- -87.03%
- 1Y return
- +62.13%
- -98.53%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 5
- 10
- Recent ratings
- 20
- 1
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Nuwellis Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Latest LIVN
- LivaNova Appoints Anne Liddy as Chief Legal Officer
- SEC Form SD filed by LivaNova PLC
- Director Bianchi Francesco sold $136,350 worth of Ordinary Shares (1,800 units at $75.75), decreasing direct ownership by 20% to 7,228 units (SEC Form 4)
- LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
- LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC
Latest NUWE
- Nuwellis Announces Closing of $6.0 Million Registered Public Offering
- SEC Form 424B4 filed by Nuwellis Inc.
- Nuwellis Announces Pricing of $6 Million Public Offering
- SEC Form S-1MEF filed by Nuwellis Inc.
- SEC Form EFFECT filed by Nuwellis Inc.
- Amendment: SEC Form S-1/A filed by Nuwellis Inc.
- SEC Form FWP filed by Nuwellis Inc.
- Amendment: SEC Form S-1/A filed by Nuwellis Inc.
- SEC Form SD filed by Nuwellis Inc.
- SEC Form S-1 filed by Nuwellis Inc.